American Capital Advisory’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
Other funds holding ALNY
American Capital Advisory's ALNY Position: Q2 2026 in Review
American Capital Advisory increased its Alnylam Pharmaceuticals (ALNY) stake by 40% in Q2 2026, buying an estimated $603 and bringing the position to 7 shares worth $2.11K. The position accounts for ﹤0.01% of the portfolio, ranked #615.
American Capital Advisory first reported a position in ALNY in Q2 2025 and has held it in 5 quarters since. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- American Capital Advisory held 7 shares of Alnylam Pharmaceuticals worth $2.11K as of Q2 2026.
- American Capital Advisory bought 2 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $603.
- Alnylam Pharmaceuticals made up ﹤0.01% of American Capital Advisory's portfolio in Q2 2026, its #615 holding.
- American Capital Advisory first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
- 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.